Search research articles
Contact Us
Filters
Showing results (271-280 of 307) with videos related to
Page
of 31
Sort By:
Allergy
|
July 4, 2014
First European data from the network of severe allergic reactions (NORA)
M Worm, A Moneret-Vautrin, K Scherer, et al.
Allergy
|
November 20, 2014
Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis
K Brockow, S Schallmayer, K Beyer, et al.
Clinical and Translational Allergy
|
November 10, 2016
Standardization of double blind placebo controlled food challenge with soy within a multicentre trial
R Treudler, A Franke, A Schmiedeknecht, et al.
Allergy
|
February 21, 2013
Evaluation of commercial skin prick test solutions for selected occupational allergens
V van Kampen, F de Blay, I Folletti, et al.
Allergy
|
July 4, 2017
Meat allergy associated with galactosyl-α-(1,3)-galactose (α-Gal)-Closing diagnostic gaps by anti-α-Gal IgE immune profiling
U Jappe, S Minge, B Kreft, et al.
Allergy
|
November 21, 2013
Management of anaphylaxis: a systematic review
S Dhami, S S Panesar, G Roberts, et al.
Arthritis Care & Research
|
June 1, 2019
Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis
D Belz, P Moinzadeh, G Riemekasten, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
September 8, 2018
[Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany]
E Haufe, S Abraham, A Heratizadeh, et al.
The British Journal of Dermatology
|
December 29, 2015
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies
N Hunzelmann, G Riemekasten, M O Becker, et al.
The British Journal of Dermatology
|
October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
Page
of 31
Search research articles
Search
Showing results (271-280 of 307) with videos related to
Sort By:
Page
of 31
Allergy
|
July 4, 2014
First European data from the network of severe allergic reactions (NORA)
M Worm, A Moneret-Vautrin, K Scherer, et al.
Allergy
|
November 20, 2014
Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis
K Brockow, S Schallmayer, K Beyer, et al.
Clinical and Translational Allergy
|
November 10, 2016
Standardization of double blind placebo controlled food challenge with soy within a multicentre trial
R Treudler, A Franke, A Schmiedeknecht, et al.
Allergy
|
February 21, 2013
Evaluation of commercial skin prick test solutions for selected occupational allergens
V van Kampen, F de Blay, I Folletti, et al.
Allergy
|
July 4, 2017
Meat allergy associated with galactosyl-α-(1,3)-galactose (α-Gal)-Closing diagnostic gaps by anti-α-Gal IgE immune profiling
U Jappe, S Minge, B Kreft, et al.
Allergy
|
November 21, 2013
Management of anaphylaxis: a systematic review
S Dhami, S S Panesar, G Roberts, et al.
Arthritis Care & Research
|
June 1, 2019
Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis
D Belz, P Moinzadeh, G Riemekasten, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
September 8, 2018
[Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany]
E Haufe, S Abraham, A Heratizadeh, et al.
The British Journal of Dermatology
|
December 29, 2015
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies
N Hunzelmann, G Riemekasten, M O Becker, et al.
The British Journal of Dermatology
|
October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
Page
of 31